Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basimglurant in children, adolescents, and young adults with TSC
2024-512611-53-00Phase 2Completed
- Sponsor
- Noema Pharma
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of basimglurant in tuberous sclerosis complex (TSC), epilepsy and Drug-resistant epilepsy (DRE) (2 arms), sponsored by Noema Pharma. Primary endpoint: Monthly seizure counts of countable seizure types (per 28 days). Started Sep 2024; status: completed.
02
Drugs
basimglurant
03
Conditions
tuberous sclerosis complex (TSC)epilepsyDrug-resistant epilepsy (DRE)
Beyond the preview
Go deeper on 2024-512611-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512611-53-00.